A federal judge has granted final approval to SmithKline Beecham's $65 million settlement of an antitrust class action by consumers who said they paid inflated prices for Paxil, a popular anti-depressant. The suit alleged that SmithKline illegally maintained a monopoly by filing a series of "sham" patent suits to delay generic versions from reaching market. The judge also awarded $19 million in attorney fees to plaintiffs lawyers who logged more than 17,000 hours on the case since December 2000.
$65 Million Settlement OK'd in Paxil Antitrust Lawsuit
The Legal Intelligencer
April 27, 2005
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.